Hemostemix Inc. (HEM.V)

CAD 0.1

(26.67%)

Long Term Debt Summary of Hemostemix Inc.

Hemostemix Inc.'s latest annual long term debt in 2023 was 4.32 Million CAD , up 4.74% from previous year.
Hemostemix Inc.'s latest quarterly long term debt in 2024 Q1 was 4.46 Million CAD , up 3.36% from previous quarter.
Hemostemix Inc. reported annual long term debt of 4.12 Million CAD in 2022, up 178.43% from previous year.
Hemostemix Inc. reported annual long term debt of 1.48 Million CAD in 2021, down 0.0% from previous year.
Hemostemix Inc. reported quarterly long term debt of 4.46 Million CAD for 2024 Q1, up 3.36% from previous quarter.
Hemostemix Inc. reported quarterly long term debt of 4.32 Million CAD for 2023 FY, up 4.74% from previous quarter.

Annual Long Term Debt Chart of Hemostemix Inc. (2023 - 2013)

Historical Annual Long Term Debt of Hemostemix Inc. (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	4.32 Million CAD	4.74%
2022	4.12 Million CAD	178.43%
2021	1.48 Million CAD	0.0%
2020	- CAD	0.0%
2019	- CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	-100.0%
2016	312.65 Thousand CAD	0.0%
2015	- CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	4.61 Million CAD	3.36%
2024 Q1	4.46 Million CAD	3.36%
2023 FY	4.32 Million CAD	4.74%
2023 Q2	4.18 Million CAD	6.7%
2023 Q1	3.92 Million CAD	-4.93%
2023 Q4	4.32 Million CAD	0.72%
2023 Q3	4.29 Million CAD	2.52%
2022 Q1	1.44 Million CAD	-2.73%
2022 FY	4.12 Million CAD	178.43%
2022 Q2	2.54 Million CAD	76.3%
2022 Q3	2.63 Million CAD	3.81%
2022 Q4	4.12 Million CAD	56.41%
2021 Q3	1.32 Million CAD	3.46%
2021 Q1	- CAD	0.0%
2021 Q2	1.28 Million CAD	0.0%
2021 FY	1.48 Million CAD	0.0%
2021 Q4	1.48 Million CAD	11.85%
2020 Q2	- CAD	0.0%
2020 Q3	- CAD	0.0%
2020 Q4	- CAD	0.0%
2020 Q1	- CAD	0.0%
2020 FY	- CAD	0.0%
2019 Q4	- CAD	0.0%
2019 FY	- CAD	0.0%
2019 Q3	- CAD	0.0%
2019 Q2	- CAD	0.0%
2019 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q4	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q1	- CAD	0.0%
2017 Q1	348.08 Thousand CAD	11.33%
2017 Q2	387.98 Thousand CAD	11.46%
2017 Q3	- CAD	-100.0%
2017 Q4	- CAD	0.0%
2017 FY	- CAD	-100.0%
2016 Q4	312.65 Thousand CAD	-49.53%
2016 FY	312.65 Thousand CAD	0.0%
2016 Q1	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q3	619.5 Thousand CAD	0.0%
2015 Q1	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 FY	- CAD	0.0%
2014 Q2	- CAD	0.0%
2014 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q3	- CAD	0.0%
2013 FY	- CAD	0.0%
2013 Q2	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 Q4	- CAD	0.0%
2013 Q1	- CAD	0.0%
2012 Q4	- CAD	0.0%
2012 Q3	- CAD	0.0%

Peer Long Term Debt Comparison of Hemostemix Inc.

Name	Long Term Debt	Long Term Debt Difference
Arch Biopartners Inc.	703.92 Thousand CAD	-513.919%
Covalon Technologies Ltd.	919.08 Thousand CAD	-370.199%
Universal Ibogaine Inc.	1.73 Million CAD	-148.695%
Kane Biotech Inc.	1.3 Million CAD	-231.795%
MedMira Inc.	2.95 Million CAD	-46.134%
Marvel Biosciences Corp.	1 Million CAD	-332.15%
NervGen Pharma Corp.	105.6 Thousand CAD	-3992.178%
XORTX Therapeutics Inc.	- CAD	-Infinity%